1.5 years retrospective study of effectiveness of NBUVB in the treatment of chronic plaque psoriasis in Tuanku Ja'afar Seremban Hospital
Malaysian Journal of Dermatology 2011;27(-):19-19
Objective
The aim of the study is to determine the demographic data of local psoriasis patients treated with NBUVB, their responses
and complication to the treatment, factors which affect the effectiveness of NBUVB and duration of remission post
treatment.
Material and Methods
A retrospective analysis of patients with chronic plaque psoriasis treated with NBUVB between January 2005 to December
2009 was conducted at the dermatology clinic, Tuanku Ja’afar Seremban Hospital. Patients’ demographic data and clinical
characteristics, concurrent topical treatment, responses to NBUVB, complications and recurrences were reviewed.
Results
A total of 33 chronic plaque psoriasis patients treated with NBUVB were reviewed. There were 14 female patients and
19 male patients in the group. Their ages ranged from 27 to 78 years old (mean age = 51.8, sd = 12.7). 16 of them were
Malays (Fitzpatrick skin phototype IV generally), 12 of them were Chinese (skin phototype III) and only 5 of them were
Indians (skin phototype V and VI). The duration of disease before starting phototherapy ranged from 3 to 30 years (mean
= 12.3, sd = 6.5). All patients had improvement after phototherapy where 9 of them achieved grade 4 response (complete
flattening of plaque), 12 had grade 3 response (complete flattening except border of plaque), 11 had grade 2 response
(partial flattening, less scale and erythema) while 1 with grade 1 response(slightly less scale and erythema). Only 1 of the
patients had adverse reaction from phototherapy with pruritus post phototherapy. Durations of remission of plaque in
response to phototherapy ranges from 1 month to 60 months (mean = 10, sd = 12.9).
Conclusion
NBUVB is a good treatment option for patients with chronic plaque psoriasis as most of the patients have some remission
of plaques. It is safe and well tolerable with only 1 patient from our study had adverse reaction from the treatment.
2.Atypical Presentation of Cutaneous Larva Migrans: A Case Report & Literature Review
Kean Pan ONG ; Wooi Chiang TAN ; Yew Thong CHONG ; Yek Huan KHOR ; Lee Chin CHAN
Malaysian Journal of Dermatology 2017;39(Dec):56-58
Cutaneous larva migrans, also known as “migrant linear epidermitis”, “beach worm”, “migranthelminthiasis”, “dermatitis serpiginosus” or “creeping eruption”. It is a zoonosis which caused byaccidental percutaneous inoculation of helminth larvae, usually parasites of the small intestines of catsand dogs. It typically presents as an itchy, erythematous, serpiginous, cutaneous eruption. We describea case of disseminated and extensive infection of cutaneous larva migrans in a 21-year-old traveler,leading a delay in diagnosis and treatment.
3.A 10-years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in Penang, Malaysia
Chai Har LOO ; Wooi Chiang TAN ; Yek Huan KHOR ; Lee Chin CHAN
The Medical Journal of Malaysia 2018;73(2):73-77
Introduction: Severe cutaneous adverse drug reactions(SCARs) are not uncommon and potentially lifethreatening.Our objective is to study the patientcharacteristics, the pattern of implicated drugs andtreatment outcome among patients with SCARs.Methods: A 10-year retrospective analysis of SCARscases in Penang General Hospital was carried out fromJanuary 2006 to December 2015. Data collection is basedon the Malaysian Adverse Drug Reactions AdvisoryCommittee registry and dermatology clinic records.Results: A total of 189 cases of SCARs were encountered(F:M ratio; 1.2:1.0; mean age of 45 year). The commonestmanifestation was Stevens-Johnson Syndrome [SJS](55.0%), followed by toxic epidermal necrolysis [TEN](23.8%), drug rash with eosinophilia and systemicsymptoms [DRESS] (12.7%), acute generalisedexanthematous pustulosis [AGEP] (4.8%), SJS/TENoverlap syndrome (2.6%) and generalised bullous fixeddrug eruptions [GBFDE] (1.1%). Mean time to onset forTEN/SJS/Overlap syndrome was 10.5±13 days; AGEP,three days; GBFDE, 2.5±0.7 days, and DRESS, 29.4±5.7days. The most common drugs implicated wereantibiotics (33.3%), followed by allopurinol (18.9%) andanticonvulsant (18.4%). Out of 154 cases ofSJS/TEN/overlap syndrome, allopurinol was thecommonest causative agents (20.1%). In DRESS,allopurinol accounts for 45.8% of the cases. The mortalityrate in SJS, TEN and DRESS were 1.9%, 13.3% and 12.5%respectively. No mortality was observed in AGEP andGBFDE.Conclusion: The commonest manifestations of SCARs inour setting were SJS, TEN and DRESS. Allopurinol wasthe most common culprit. Thus, judicious allopurinol useis advocated and pre-emptive genetic screening for HLAB*5801 should be consider
4.Management of Atopic Eczema in primary care
Ainol Haniza Kherul Anuwar ; Azura Mohd Affandi ; Ch&rsquo ; ng Chin Chwen ; Dawn Ambrose ; Heah Sheau Szu ; Khor Yek Huan ; Lalitha Pillay a/p B. Gopinathan ; Leow Wooi Leong ; Mohd. Aminuddin Mohd. Yusof ; Noor Zalmy Azizan ; Sabeera Begum ; Siti Shafatun Mohsin ; Tan Wooi Chiang ; Tarita Taib ; Wong Ping Foo ; Zaridah Zainuri ; Siti Mariam Tukimin
Malaysian Family Physician 2020;15(1):39-43
Introduction: Atopic eczema (AE) is a common infammatory skin dermatosis that is increasing
in prevalence. However, it can present in various clinical presentations, which leads to challenges
in the diagnosis and treatment of the condition, especially in a primary care setting. Te Clinical
Practice Guidelines on the Management of Atopic Eczema was developed by a multidisciplinary
development group and approved by the Ministry of Health Malaysia in 2018. It covers the aspects
of diagnosis, severity assessment, treatment, and referral.